Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT00939523 : Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy
PhasePhase 2
AgesMin: 18 Years Max: N/A
Eligibility
Inclusion Criteria:

- Patients with nonfunctioning adenomas who have undergone at least one prior surgical
resection and have demonstrated recurrence on MRI

- Patients with prolactinomas who are resistant to dopamine agonist therapy

- Patients with malignant pituitary tumors

- Patients with visual field deficits and/or compression of the optic chiasm must be
stable for at least 6 months

Exclusion Criteria:

- Patients with compromised visual fields and/or compression of the optic chiasm on MRI
that has not been stable for last 6 months.

- Patients that have reduced left ventricular ejection fraction less than 50%

- Patients with moderate to severe hepatic impairment

- Patients that are pregnant or lactating

- Patients under the age of 18

- Active hepatitis

- Known previous HIV Positive

- Concurrent cancers

- Life expectancy less than one year
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT00939523      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740